JCO Precis Oncol 2023 May
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression.
Related Questions
New answer by Medical Oncologist at Harvard Medical School (January 2, 2024)
For patients with HR+/HER2- breast cancer who develop metastatic progression on (or shortly after receiving) aromatase inhibitor therapy, fulvestrant with a CDK4/6 inhibitor (...